Gefitinib/osimertinibDrug resistance and lack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1902卷 / 1期

关键词：

D O I：

10.1007/s40278-022-13363-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：219 / 219

相关论文

共 50 条

[31] AntineoplasticsAcquired resistance and lack of efficacy: case report
Reactions Weekly, 2022, 1916 (1) : 41 - 41
[32] AntineoplasticsAcquired resistance and lack of efficacy: case report
Reactions Weekly, 2021, 1867 (1) : 48 - 48
[33] AntineoplasticsDrug resistance and lack of efficacy: case report
Reactions Weekly, 2022, 1917 (1) : 74 - 74
[34] AntibacterialsDevelopment of resistance and lack of efficacy: case report
Reactions Weekly, 2021, 1848 (1) : 48 - 48
[35] AntineoplasticsDrug resistance and lack of efficacy: case report
Reactions Weekly, 2022, 1902 (1) : 53 - 53
[36] AntiviralsDrug resistance and lack of efficacy: case report
Reactions Weekly, 2021, 1866 (1) : 64 - 64
[37] AntineoplasticsAcquired resistance and lack of efficacy : case report
Reactions Weekly, 2022, 1930 (1) : 57 - 57
[38] AntineoplasticsDrug resistance and lack of efficacy: case report
Reactions Weekly, 2023, 1953 (1) : 45 - 45
[39] AntibacterialsDevelopment of resistance and lack of efficacy: case report
Reactions Weekly, 2021, 1836 (1) : 69 - 69
[40] AntineoplasticsDrug resistance and lack of efficacy : case report
Reactions Weekly, 2023, 1953 (1) : 44 - 44

← 1 2 3 4 5 →